Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Ruth Oratz, MD
Advertisement
Articles by Ruth Oratz, MD
Advertisement
Latest Updated Articles
Dr. Oratz on PARP Inhibitors to Treat Patients With Breast CancerPublished: May 14th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
3
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
4
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
5
